- Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer.
- Navitski A, Al-Rawi DH, Liu Y, Rubinstein MM, Friedman CF, Rampal RK, Mandelker DL, Cadoo K, O'Cearbhaill RE.
- Gynecol Oncol Rep. 2021 Oct 5;38:100873. doi: 10.1016/j.gore.2021.100873. eCollection 2021 Nov.
- PMID: 34926756
- PubMed abstract
- Case report
- Free PMC article
- Free Full Text